Evidence map›Paper›PMID 32257625›Full record

ReviewBioResearch open access2020

Klotho Pathways, Myelination Disorders, Neurodegenerative Diseases, and Epigenetic Drugs.

Walter H Moos, Douglas V Faller, Ioannis P Glavas, David N Harpp, Iphigenia Kanara, Anastasios N Mavrakis, Julie Pernokas, Mark Pernokas, Carl A Pinkert, Whitney R Powers and 6 more

Open access · diamondAbstract readReview
In one paragraph

Review in BioResearch open access, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Multiple Sclerosis: Inflammatory and Neuroglial Aspects.Current issues in molecular biology · 2023
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 3 countries.

Walter H MoosDepartment of Pharmaceutical Chemistry, School of Pharmacy, University of California San Francisco, San Francisco, San Francisco, California.
Douglas V FallerDepartment of Medicine, Boston University School of Medicine, Boston, Massachusetts.
Ioannis P GlavasDepartment of Ophthalmology, New York University School of Medicine, New York, New York.
David N HarppDepartment of Chemistry, McGill University, Montreal, Canada.
Iphigenia KanaraHellenic Republic, Ministry of Foreign Affairs, Athens, Greece.
Anastasios N MavrakisDepartment of Medicine, Tufts University School of Medicine, St. Elizabeth's Medical Center, Boston, Massachusetts.
Julie PernokasAdvanced Dental Associates of New England, Woburn, Massachusetts.
Mark PernokasAdvanced Dental Associates of New England, Woburn, Massachusetts.
Carl A PinkertDepartment of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, Alabama.
Whitney R PowersDepartment of Health Sciences, Boston University, Boston, Massachusetts.
Konstantina SampaniDepartment of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
Kosta SteliouCancer Research Center, Boston University School of Medicine, Boston, Massachusetts.
Demetrios G VavvasDepartment of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
Robert J ZamboniDepartment of Chemistry, McGill University, Montreal, Canada.
Krishna KodukulaShangPharma Innovation, Inc., South San Francisco, California.
Xiaohong ChenDepartment of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
Boston University · USAdvanced Pharma · USMassachusetts Eye and Ear Infirmary · USMcGill University · CAAuburn University · USJoslin Diabetes Center · USMinistry of Education and Religious Affairs · GRNew York University · USPrincipia Biopharma (United States) · USSt. Elizabeth's Medical Center · USUniversity of California, San Francisco · US

Funding

Necroptosis, neuroprotection and axonal regeneration in retina ganglion cell injuryR01EY025362 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI VAVVAS, DEMETRIOS · 2015 to 2018
$1.5M
The Third International Biennial Symposium on Ocular Regeneration: Tissue Engineering and the EyeR13EY029551 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI VAVVAS, DEMETRIOS · 2018 to 2018
$24k
Second International Biennial Symposium on Ocular RegenerationR13EY027184 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI VAVVAS, DEMETRIOS · 2016 to 2016
$20k
NEI NIH HHS R01 EY025362NEI NIH HHS R13 EY027184NEI NIH HHS R13 EY029551
6 · The paper itself

Abstract

In this review we outline a rationale for identifying neuroprotectants aimed at inducing endogenous Klotho activity and expression, which is epigenetic action, by definition. Such an approach should promote remyelination and/or stimulate myelin repair by acting on mitochondrial function, thereby heralding a life-saving path forward for patients suffering from neuroinflammatory diseases. Disorders of myelin in the nervous system damage the transmission of signals, resulting in loss of vision, motion, sensation, and other functions depending on the affected nerves, currently with no effective treatment.

Indexed as

amyotrophic lateral sclerosisKlothomitochondriamultiple sclerosisneurodegenerative disease

Identifiers

PMID32257625
PMCPMC7133426
OpenAlexW3014418129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.